Following the transaction, Xellia will revert to Danish ownership with headquarters in Denmark.
Xellia develops and manufactures anti-infective therapies for multi-drug resistant infections and supplies Vancomycin and Colistimethate Sodium (CMS).
Novo’s investment will allow Xellia to improve its focus on R&D and expand its global production footprint to further scale its finished-dosage-form (FDF) business.
Xellia CEO Carl-Åke Carlsson said, "Together with Novo we can strengthen the positive development that Xellia has achieved over the past few years, and at the same time the investment by Novo will help accelerate our developments further."
Novo CEO Henrik Gürtler said, "The products that Xellia supplies are critical life-saving treatments for many patients around the globe, and are manufactured by use of fermentation technologies, which is a manufacturing approach similar to that of Novo Nordisk, Novozymes and Chr. Hansen."
All the Xellia’s products are manufactured using fermentation-based biological processes at facilities in Denmark, Norway, Hungary and China.